BioSpace News Archive

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year 2020.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S. financial markets open.

Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2020, and highlighted recent accomplishments

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and year ended December 31, 2020 and provided a corporate update.

Illumina, Inc. (NASDAQ: ILMN), along with researchers at the University of Colorado and Harvard Pilgrim Health Care (HPHC), reported study results evaluating the impact of an innovative risk-sharing agreement that opened insurance coverage of non-invasive prenatal testing (NIPT) for pregnant women under the age of 35.

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the fourth quarter and year ended December 31, 2020.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call at 8:00 a.m. ET on Friday, March 12, 2020.

NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation technology to treat neurological and neuropsychiatric disorders, announced that the following patents have issued or received notices of allowance in Canada and Japan:

Invacare Corporation priced $110 million aggregate principal amount of 4.25% convertible senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of three lots of Phenylephrine Hydrochloride Injection, USP (10 mg/mL)